Protocol Ledger

NCT03532542 · Phase III · TERMINATED

An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular Dystrophy

Interventional Phase III clinical trial protocol NCT03532542 sponsored by Sarepta Therapeutics in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-08-02 Enrollment: 171 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03532542
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)171 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03532542
Protocol FieldVerified Registry Value
NCT IdentifierNCT03532542
Consolidated Lead SponsorSarepta Therapeutics
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment171 participants (ACTUAL)
Registered Start Date2018-08-02
WhyStopped ClassificationSafety / Toxicity / Adverse Events

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Sarepta Therapeutics across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI